Literature DB >> 28097299

Evaluation of Potencies of Immune Globulin Products Against Hepatitis A.

Alexandra Tejada-Strop1, Maria Isabel Costafreda2, Zoya Dimitrova1, Gerardo G Kaplan2, Chong-Gee Teo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28097299     DOI： 10.1001/jamainternmed.2016.9057

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  7 in total

Review 1.  The History of Hepatitis A.

Authors:  Daniel Shouval
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-10-07

2.  HAVCR1 (CD365) and Its Mouse Ortholog Are Functional Hepatitis A Virus (HAV) Cellular Receptors That Mediate HAV Infection.

Authors:  Maria Isabel Costafreda; Gerardo Kaplan
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

Review 3.  Immunization against Hepatitis A.

Authors:  Daniel Shouval
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

4.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

5.  Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.

Authors:  Noele P Nelson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-15       Impact factor: 17.586

6.  Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects.

Authors:  Martin Kankam; Rhonda Griffin; Jeffrey Price; Josée Michaud; Wei Liang; Mariona Bassas Llorens; Ana Sanz; Bradley Vince; David Vilardell
Journal:  Adv Ther       Date:  2020-04-16       Impact factor: 3.845

Review 7.  The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles.

Authors:  Megan K Young
Journal:  Hum Vaccin Immunother       Date:  2019-06-19       Impact factor: 3.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.